This review aims to provide a comprehensive synthesis of current diagnostic and therapeutic strategies for advanced NSCLC, with a particular focus on ICI-based therapies in patients unselected for PD-L1 expression to evaluate the relative efficacy and safety of ICI monotherapy, chemo-immunotherapy combinations, and dual ICI regimens. The gene discussed is CD274; the disease is non-small cell lung carcinoma.